Multidisciplinary
Teams

Cutting-edge Models
and Technologies

Clinical
Cohorts

• Studying diabetes and metabolic dysfunction-associated steatotic liver disease, which are common in Singapore, as well as chronic liver disease.
  

• Tapping on cutting-edge models and patient samples in multi-omics to create novel diagnostic biomarkers, preventive strategies and therapeutics.​

• Developing bench to bedside initiatives and ensuring that innovations are patient-centric.

Research on the diet-microbe-host interactions and their effects on cardiometabolic and vascular diseases is leading to the discovery of novel biomarkers and therapeutics.

• Our study of 800 bariatric surgery patients led to an Asian metabolic surgery diabetes remission score to guide surgical counselling and predict remission.​

• We showed that saturated fats make insulin-producing cells stressed, and food restriction can reduce this stress and improve diabetic patients’ condition.​

• We are working on increasing liver and heart regeneration to reverse fibrosis and alleviate chronic disease, as well as on controlling inflammation.

Through cutting edge models, technologies and clinical cohorts the team is developing new treatment for obesity and diabetes.

Torsten WUESTEFELD
Programme Director

Rinkoo DALAN
Clinical Co-Director